TNG:EPA
Transgene SA
€0.68
arrow_downward
-0.58%(-0.0040) 1D
Oct 19, 4:36:42 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
€0.69
High
€0.70
Low
€0.68
Mkt. cap
189.98M
Avg. vol.
111.65K
Volume
46.40K
52-wk high
€1.50
52-wk low
€0.68
EPS
-€0.17
Shares outstanding
278.56M
No. of employees
152
Open
€0.69
High
€0.70
Low
€0.68
Mkt. cap
189.98M
Avg. vol.
111.65K
Volume
46.40K
52-wk high
€1.50
52-wk low
€0.68
EPS
-€0.17
Shares outstanding
278.56M
No. of employees
152
News stories
From web sources and news partners
finance.biggo.com
·
43 minutes ago
He makes 3 decisions a year (and beat the S&P 500 for 11 years)｜My First Million
TradingView
·
33 minutes ago
S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
RealMoney Pro
·
34 minutes ago
Charting the Markets: The S&P Is Still Bullish. But for How Long?
Insider Monkey
·
1 hour ago
Apple Has Outperformed the S&P 500, but is AAPL’s 35x Valuation Getting Ahead of its Growth?
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA